Clinical safety of ultra-high-dose methylcobalamin in patients with amyotrophic lateral sclerosis: Open-label extension of a phase 2/3 randomized controlled study

What Was Tested

The paper reports a study of Cyanocobalamin (Vitamin B12), published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label, placebo-controlled and multicenter study.

Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Cyanocobalamin (Vitamin B12) study, the assignments were hidden from both participants and investigators until the end.

Everyone knew when Cyanocobalamin (Vitamin B12) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The comparison arm used a placebo, so changes seen with Cyanocobalamin (Vitamin B12) could be set against what happens without it.

The timeline in the abstract includes 52 weeks.

What Was Measured

PubMed files the paper under topics including Amyotrophic Lateral Sclerosis and Vitamin B 12.

The authors tagged it with the keywords Advanced amyotrophic lateral sclerosis, Clinical trial, Methylcobalamin, Safety and Survival.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Cyanocobalamin (Vitamin B12) over 52 weeks.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Journal of the neurological sciences), a journal based in Netherlands.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.